Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens: A case report

NeuroImmunoModulation

Volumn 13, Issue 4, 2006, Pages 205-208

  Hazrati, Saleh Mohaghegh ^a   Aghazadeh, Javad ^c   Mohtarami, Fatemeh ^a   Abouzari, Mehdi ^b,d   Rashidi, Armin ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NONE   (Iran)

Author keywords

Autoantigen; Immunotherapy; Prolactinoma; T helper 1 activator adjuvant

Indexed keywords

AUTOANTIGEN; BROMOCRIPTINE; IMMUNOLOGICAL ADJUVANT; PROLACTIN; T HELPER 1 ACTIVATOR ADJUVANT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERHIDROSIS; IMMUNOHISTOCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SKINFOLD THICKNESS; SYMPTOM; TREATMENT OUTCOME; TUMOR DIAGNOSIS;

EID: 33947496997     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100405     Document Type: Article

References (25)

1. Arafah BM, Nasrallah MP: Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001;8:287-305.
2. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy ER: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
3. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
4. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
5. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M: Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin Endocrinol (Oxf) 2006;64:542-548.
6. Hazrati SM: Effect of autoantigens and Th1-activator adjuvants on pituitary adenoma of prolactinoma. Iran J Endocrinol Metab 2002;3:22.
7. Hazrati SM: T helper-1 cell activators (G2, PC, G2F) as adjuvants (biotherapy and prevention of cancers and allergies). New Approaches to Vaccine Development (Congress), Berlin, 2005.
8. Mahaley MS Jr, Gillespie GY, Gillespie RP, Watkins PJ, Bigner DD, Wikstrand CJ, MacQueen JM, Sanfilippo F: Immunobiology of primary intracranial tumors, part 8: serological responses to active immunization of patients with anaplastic gliomas. J Neurosurg 1983;59:208-216.
9. Babiel R, Willnow P, Baer M, van Gent M, Ehrhardt V: A new enzyme immunoassay for prolactin in serum or plasma. Clin Chem 1990;36:76-80.
10. Molitch ME, Thorner MO, Wilson CB: Management of prolactinomas: overview and introduction. J Clin Endocrinol Metab 1997;82:996-1000.
11. Larner AJ: Headache induced by dopamine agonists prescribed for prolactinoma: think SUNCT! Int J Clin Pract 2006;60:360-361.
12. Levy MJ, Matharu MS, Goadsby PJ: Prolactinomas, dopamine agonists and headache: two case reports. Eur J Neurol 2003;10:169-173.
13. Liu Y, Ng K, Lillehei KO: Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 2003;10:138-147.
14. Matera L: Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 1997;4:171-180.
15. Febvre H, Maunoury R, Constans JP, Trouillas P: Delayed hypersensitivity reactions in patients bearing malignant brain tumors with human tumor cell lines grown in vitro. Int J Cancer 1972;10:221-232.
16. Mahaley MS Jr, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum JM: Immunobiology of primary intracranial tumors. Part 7. Active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg 1983;59:201-207.
17. Bloom HJ, Peckham MJ, Richardson AE, Alexander PA, Payne PM: Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer 1973;27:253-267.
18. Osada T, Fujimaki T, Takamizawa M, Tsuno NH, Kirino T, Shibata Y: Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report. Jpn J Clin Oncol 2001;31:403-406.
19. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-411.
20. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M: Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164:3902-3912.
21. Wang RF: The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269-276.
22. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
23. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li XF, Shimizu J, Fujiwara H, Hamaoka T: Transforming growth factor-β-induced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991;146:1077-1082.
24. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA: Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994;73:1882-1887.
25. Utsumi K, Takai Y, Tada T, Ohzeki S, Fujiwara H, Hamaoka T: Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 1990;145:397-403.